Treatment of CNS and pain disorders

Inactive Publication Date: 2009-03-12
XENOVA
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Valproate has a known risk of hepatic failure, particularly in young children.
Until now, such a goal has only been achieved with valproate, but at a serious price of side effects as mentioned above and contraindications (e.g. interactions with other medications and particularly potential for congenital malformations).
However, even with these options available, many patients fail to respond, or respond only partially to treatment.
Additionally, many of these agents show delayed onset of activity, so that patients are required to undergo treatment for weeks or months before receiving benefits.
Traditional therapies can also have significant side effects.
Other problematic side effects include gastrointestinal disturbances, often manifested as nausea and occasional vomiting, agitation, insomnia, weight gain, onset of diabetes, prolongation of the heart rate corrected interval (QTc), agranylocytosis, etc.
These side effects often discourage patients from following their recommended therapeutic regimen.
All classes of antidepressants are reportedly successful in treating epilepsy-related depression but may also, to a varying degree, lower seizure control and thus pose a difficulty in treating depression in epilepsy (Lowe, A, The Impact of Depression.
The nature of fibromyalgia is not well understood, with many frustrated physicians driven to accusing their patients of feigning illness.
There are few, if any, treatments available.
They can become more tolerable or less tolerable throughout daily or yearly cycles; however, many people with fibromyalgia find that, at least some of the time, the condition prevents them from performing normal activities such as driving a car or walking up stairs.
As with many other soft tissue and rheumatolgical organic disorders, there is

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Treatment of CNS and pain disorders
  • Treatment of CNS and pain disorders

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0078]Hot plate test. Male mice weighing from 25 to 30 g were used in this test. The thermal technique (hot plate analgesia meter) was used to evaluate analgesic effect after the injection of drugs or saline. The surface of the plate was maintained at a temperature of 55.0±0.5° C. Analgesic effect was determined 30 min. after compound injection. Time (in seconds) to either hind paw licking or jumping was recorded as pain response latency. To avoid the likelihood of tolerance of mice to hot plate, all mice were exposed to hot plate only once through the whole experiment. The mice were exposed to hot plate only once; either before or after injection of drug.

[0079]In this hot plate test the tetramic derivative of the invention exhibits an analgesic effect after peroral administration in mice at a dose of 50 mg / kg. A similar effect was observed with phenytoin and valproate at 100 and 500 mg / kg respectively.

example 2

[0080]Tail-flick test. The tail-flick test, using a radiant heat source was carried out to study antinociception. Each mouse was placed in an acrylic tube and its tail was laid across a Nichrome™ wire coil, which was heated by the passage of an electric current. The intensity of the current was kept at 5 mA. All animals were screened for the tail-flick response. Only those showing a flick within 4 sec were included in the study. After 1 h of final dosing, the mice were submitted to three tail-flick tests.

[0081]In this tail-flick test the tetramic derivative of the invention exhibits an analgesic effect after peroral administration.

[0082]At the highest doses tested (500 mg / kg), the tetramic derivative of the invention exhibits a relatively better analgesic effect compared to phenytoin and valproate (100 and 500 mg / kg respectively). All data were compared with the same control group.

example 3

[0083]Formalin paw test. The mice received an injection of formalin (4.5%, 20 μl) to the left hind paw. The irritation caused by the formalin injection elicits a characteristic biphasic behavioral response as quantified by the amount of time spent licking the injured paw. The first phase (˜5-10 minutes) represents direct chemical irrigation, and the second phase (˜20-30 minutes) is thought to represent pain of neuropathic origin (Tjølsen A et al. Pain (1992) 51:5-17). The two phases are separated by a quiescent period in which behavior returns to normal. The effectiveness of test compounds to reduce the painful stimuli is assessed by counting the amount of time spent licking the injured paw in the two phases.

[0084]In this inhibition of pain behavior test, the tetramic derivative of the invention displays a 5% reduction in pain score in the chronic phase at a dose of 30 mg / kg. Similar reduction was seen with gabapentin and morphine at 20 mg / kg and 1.25 mg / kg, respectively, compare

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Electrical resistanceaaaaaaaaaa
Disorderaaaaaaaaaa
Login to view more

Abstract

A method of treating a patient suffering from a condition or disorder selected from chronic pain, neuropathic pain, fibromyalgia, migraine, bipolar disorder and depression comprises the administration of a pharmacologically effective amount of 3-(phenylmethylamino-methylene)pyrrolidine-2,4-dione (I) or a pharmaceutically acceptable salt or prodrug or solvate thereof. Also disclosed is the use of (I) for the manufacture of a pharmaceutical composition for treatment of such condition or disorder.

Description

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Owner XENOVA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products